Organophosphonates

• 

  Subject Areas on Research

  • A Liver-Specific Thyromimetic, VK2809, Decreases Hepatosteatosis in Glycogen Storage Disease Type Ia. 
  • A self-adjuvanting supramolecular vaccine carrying a folded protein antigen. 
  • Accuracy of Self-Report and Pill-Count Measures of Adherence in the FEM-PrEP Clinical Trial: Implications for Future HIV-Prevention Trials. 
  • Activation of adenylate cyclase by phosphoramidate and phosphonate analogs of GTP: possible role of covalent enzyme-substrate intermediates in the mechanism of hormonal activation. 
  • Acute renal failure after initiation of tenofovir disoproxil fumarate. 
  • Adefovir dipivoxil in chronic hepatitis B: history and current uses. 
  • Alkenylation of C(sp3 )-H Bonds by Zincation/Copper-Catalyzed Cross-Coupling with Iodonium Salts. 
  • Antibody to hepatitis B surface antigen trough levels and half-lives do not differ after intravenous and intramuscular hepatitis B immunoglobulin administration after liver transplantation. 
  • Antiretroviral medications: adverse effects on the kidney. 
  • Antiretroviral preexposure prophylaxis for HIV prevention. 
  • Autotaxin-lysophosphatidic acid axis is a novel molecular target for lowering intraocular pressure. 
  • Brincidofovir (CMX001) Toxicity Associated With Epithelial Apoptosis and Crypt Drop Out in a Hematopoietic Cell Transplant Patient: Challenges in Distinguishing Drug Toxicity From GVHD. 
  • Brincidofovir for Asymptomatic Adenovirus Viremia in Pediatric and Adult Allogeneic Hematopoietic Cell Transplant Recipients: A Randomized Placebo-Controlled Phase II Trial. 
  • Changes in glomerular kidney function among HIV-1-uninfected men and women receiving emtricitabine-tenofovir disoproxil fumarate preexposure prophylaxis: a randomized clinical trial. 
  • Changes in proteinuria and albuminuria with initiation of antiretroviral therapy: data from a randomized trial comparing tenofovir disoproxil fumarate/emtricitabine versus abacavir/lamivudine. 
  • Comparative efficacy of nucleoside/nucleotide reverse transcriptase inhibitors in combination with efavirenz: results of a systematic overview. 
  • Copper-catalyzed α-amination of phosphonates and phosphine oxides: a direct approach to α-amino phosphonic acids and derivatives. 
  • Crystal structure of farnesyl protein transferase complexed with a CaaX peptide and farnesyl diphosphate analogue. 
  • Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. 
  • Design of tenofovir-UC781 combination microbicide vaginal gels. 
  • Discovery of [(3-bromo-7-cyano-2-naphthyl)(difluoro)methyl]phosphonic acid, a potent and orally active small molecule PTP1B inhibitor. 
  • Economic evaluation of ART in resource-limited countries. 
  • Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection. 
  • Expression and site-directed mutagenesis of the phosphatidylcholine-preferring phospholipase C of Bacillus cereus: probing the role of the active site Glu146. 
  • FEM-PrEP: adherence patterns and factors associated with adherence to a daily oral study product for pre-exposure prophylaxis. 
  • Fanconi syndrome accompanied by renal function decline with tenofovir disoproxil fumarate: a prospective, case-control study of predictors and resolution in HIV-infected patients. 
  • HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. 
  • Hepatitis B virus viral load and treatment decision. 
  • Identification of cognate ligands for the Escherichia coli phnD protein product and engineering of a reagentless fluorescent biosensor for phosphonates. 
  • Infant growth outcomes after maternal tenofovir disoproxil fumarate use during pregnancy. 
  • Kidney disease in patients with HIV infection and AIDS. 
  • Kinetics of irreversible activation of adenylate cyclase of fat cell membranes by phosphonium and phosphoramidate analogs of gtp1. 
  • Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. 
  • Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals. 
  • Model synthesis of nucleoside boranophosphoramidate with amino acid for prodrug purpose. 
  • Multicompartmental pharmacokinetic model of tenofovir delivery by a vaginal gel. 
  • Newer treatments for HIV in children. 
  • Perception of HIV risk and adherence to a daily, investigational pill for HIV prevention in FEM-PrEP. 
  • Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. 
  • Pharmacokinetics and safety of intravesicular cidofovir in allogeneic HSCT recipients. 
  • Pharmacokinetics of antiretroviral regimens containing tenofovir disoproxil fumarate and atazanavir-ritonavir in adolescents and young adults with human immunodeficiency virus infection. 
  • Phase II study of amonafide in advanced pancreatic adenocarcinoma. 
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. 
  • Phosphonylmethoxyalkyl purine and pyrimidine derivatives for treatment of opportunistic cytomegalovirus and herpes simplex virus infections in murine AIDS. 
  • Preexposure prophylaxis for HIV infection among African women. 
  • Progressive multifocal leukoencephalopathy following heightened immunosuppression after lung transplant. 
  • Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. 
  • Role of farnesyltransferase in ABA regulation of guard cell anion channels and plant water loss. 
  • Safety and efficacy of CMX001 as salvage therapy for severe adenovirus infections in immunocompromised patients. 
  • Short communication: Inadequate vitamin D exacerbates parathyroid hormone elevations in tenofovir users. 
  • Simplified maintenance therapy with abacavir/lamivudine/zidovudine plus tenofovir after sustained HIV load suppression: four years of follow-up. 
  • Stepped-dose protocol of cidofovir therapy in recurrent respiratory papillomatosis in children. 
  • Structured treatment interruptions with tenofovir monotherapy for simian immunodeficiency virus-infected newborn macaques. 
  • Synthesis and evaluation of a phosphonate analogue of the soluble guanylate cyclase activator YC-1. 
  • Synthesis of new classes of boron-containing nucleotides. 
  • Synthesis of oligonucleoside boranophosphates via an H-phosphonate method without nucleobase protection. 
  • Tenofovir alafenamide for HIV infection: is less more? 
  • The SATE pronucleotide approach applied to acyclovir: part II. Effects of bis(SATE)phosphotriester derivatives of acyclovir on duck hepatitis B virus replication in vitro and in vivo. 
  • The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years. 
  • The science of being a study participant: FEM-PrEP participants' explanations for overreporting adherence to the study pills and for the whereabouts of unused pills. 
  • Towards establishing indicative values for metabolites of organophosphate ester contaminants in human urine. 
  • Urinary metabolites of organophosphate flame retardants: temporal variability and correlations with house dust concentrations. 
  • Urine processing impacts uric acid level in HIV-infected adults: implications for diagnosing tenofovir-associated proximal tubulopathy. 
  • Urolithiasis under atazanavir boosted and tenofovir therapy: a case report. 
  • Vaginal deployment and tenofovir delivery by microbicide gels. 
  • Vascular smooth muscle cell migration induced by domains of thrombospondin-1 is differentially regulated. 
• 

  Keywords of People

  • Bennett, Vann, George Barth Geller Distinguished Professor of Molecular Biology, Duke Cancer Institute